Loading...Loading...August 26, 2025
Two Humira biosimilars — Hadlima and adalimumab-aaty (an unbranded version of Yuflyma) — will be preferred on all plan formularies starting Jan. 1, 2026. ASO groups will transition to Humira biosimilars upon renewal on or after Jan. 1, 2026.
Humira biosimilars have been available since 2023, but recent changes in the marketplace have made them more cost competitive.
These biosimilars provide the same experience for members as Humira, including administration method, efficacy and side effect profile, while offering cost advantages.
Most members will have pre-authorizations transitioned to the preferred biosimilar products effective Jan. 1, 2026. Members of ASO groups will transition on their plan’s renewal date. Affected members will receive notification letters about this formulary change in advance of the transition.
In the unlikely event a member doesn’t tolerate a biosimilar, their doctor may request pre-authorization for Humira.